

OPTIMIZING HEART FAILURE OUTCOMES BY ADDRESSING IRON DEFICIENCY

Managed Care Implications and Considerations
in the Emerging Era of Intravenous Iron



Activity Overview

This adaptive educational activity is targeted to managed care professionals, physicians, and specialty pharmacists attending the 2021 Academy of Managed Care Pharmacy (AMCP) Annual Meeting. Activity attendees will be given the opportunity to virtually interact with world-renowned expert faculty across all clinically relevant aspects of iron deficiency (ID) management in the setting of comorbid heart failure (HF). The session will begin with a thorough review of the pathophysiologic underpinnings of ID in HF, specifically the role of hepcidin in hyperinflammatory states and the subsequent implications on iron supplementation approaches. The robust prognostic implications and outcomes manifestations of ID in HF, including functional capacity, quality of life, and morbidity and mortality will also be reviewed in detail as a means of providing a foundational knowledge base. In the remainder of the educational session, activity attendees will appraise existing and emerging clinical trial data of IV iron therapies for ID in HF, and then provide a dynamic, case-based opportunity for attendees to apply the information they have learned into real-world clinical scenarios. Lastly, attendees will get to pilot our innovative guidance flowchart as an educational resource and clinical tool for managing ID in HF. All clinical aspects of this presentation will be augmented with cost considerations and implications at every level, allowing for a relevant and impactful educational experience for patient-facing and non-patient-facing clinicians and managed care professionals alike.

Learning Objectives

- Discuss the basic principles of iron metabolism and absorption, and understand the complex pathophysiology of iron deficiency in heart failure, with a focus on inflammation, hepcidin, and how these principles apply to treatment.
- Recognize the robust impact of comorbid ID and HF, and describe the practical *prognostic* manifestations of ID on patient functional capacity, quality of life, and morbidity and mortality outcomes.
- Review the essential utility of serum ferritin and transferrin saturation (TSAT) as diagnostic laboratory indices for ID and differentiate the practical distinctions between *functional* and *absolute* iron deficiency.
- Appraise existing, ongoing, and planned clinical trials of IV iron therapies for ID in HF, and identify pivotal trials that have influenced current practice and consensus guidelines for ID management in HF (ESC and AHA).
- Distinguish among the FDA-approved IV iron agents, including the nuances and idiosyncrasies that yield unique clinical utility and impact.
- Using an adaptive case-based format, analyze the role of hepcidin in hyperinflammatory states and the subsequent impact this has on the clinical utility of oral vs IV iron supplementation modalities in heart failure.

Target Audience

This adaptive educational initiative is targeted to managed care professionals, physicians, and specialty pharmacists attending the 2021 AMCP virtual meeting.

Faculty

Javed Butler, MD, MPH, MBA (Activity Chair)

Professor and Chairman, Department of Medicine
University of Mississippi
Jackson, Mississippi

Javed Butler, MD, MPH, MBA, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Center in Jackson Mississippi. He is also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.

He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at

the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and Master in Business Administration from Emory University.

Dr. Butler is Board Certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association. Dr. Butler has authored more than 550 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals. He has been cited numerous times in America's Best Doctors List.

Muthiah Vaduganathan, MD, MPH

Harvard Medical School
Brigham and Women's Hospital
Cardiovascular Medicine
Boston, Massachusetts

Dr. Vaduganathan is a cardiologist at Brigham and Women's Hospital and Harvard Medical School (Boston, MA) He is interested in drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 275 peer-reviewed publications.

Dr. Vaduganathan serves on the editorial board of the European Journal of Heart Failure and JACC Heart Failure (Social Media/CME Editor). He serves on the ACCF/AHA Task Force on Performance Measures and is a co-chair on an FDA Think Tank on improving future clinical trials in HF. He participates as a Clinical Endpoints Committee member for ongoing advanced-phase trials in HF/post-MI LV dysfunction.

Katherine E. Di Palo, PharmD, FAHA, FHFS, BCACP, BCGP

Clinical Program Manager
Hospital Readmissions Reduction Program
Montefiore Medical Center
Assistant Professor of Medicine
Albert Einstein College of Medicine
New York, New York

Dr. Katherine E. Di Palo is a Clinical Pharmacy Specialist and clinical program manager for the Hospital Readmissions Reduction Program at Montefiore Medical Center. After receiving her Doctor of Pharmacy from the University at Buffalo she completed a post-graduate residency in Pharmacy Practice and obtained Board Certification in Ambulatory Care and Geriatrics.

Dr. Di Palo is the current Chair of the American Heart Association Council on Clinical Cardiology Clinical Pharmacology Committee and is an active member of the Heart Failure Society of America Advocacy Committee.

Planner and Faculty Disclosures

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners

Katherine E. Di Palo, PharmD, FAHA, FHFS, BCACP, BCGP—has no relevant financial relationships to disclose in relation to the content of this activity.

Muthiah Vaduganathan, MD, MPH—has disclosed that he is a consultant for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, and Relypsa and has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, and Relypsa and has participated in speaker engagements with Novartis.

Presenters

Javed Butler, MD, MPH, MBA—has disclosed that he is a consultant for Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, and Vifor.

Katherine E. Di Palo, PharmD, FAHA, FHSA, BCACP, BCGP—has no relevant financial relationships to disclose in relation to the content of this activity.

Muthiah Vaduganathan, MD, MPH—has disclosed that he is a consultant for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, and Relypsa and has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, and Relypsa and has participated in speaker engagements with Novartis.

Reviewers

Ankeet S. Bhatt, MD, MBA—has no relevant financial relationships to disclose in relation to the content of this activity.

Kim Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE, CLS—has no relevant financial relationships to disclose in relation to the content of this activity.

Accreditation

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME):

CEC designates this live educational activity for a maximum of 1.5 *AMA PRA Category Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)

This application-based activity is approved for 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit JA0007101-0000-21-003-L01-P.



Presented by Creative Educational Concepts

Supported by an independent educational grant from American Regent.

Satellite Symposia are developed outside of the official continuing pharmacy education program at AMCP 2021. The content of these Satellite Symposia and the opinions expressed by the presenters are those of the sponsor and/or presenters and not necessarily those of the AMCP.

held in conjunction with

